Valeant Soars on Medicis Buyout

Shares of Valeant Pharmaceuticals VRX are higher on Tuesday after the company agreed to acquire Medicis Pharmaceutical MRX for $44 per share, sending that stock more than 38% higher on the session. Investors are clearly pleased with the deal, as VRX has added nearly 15% in the wake of the announcement. While it is not exactly unusual for a company's stock price to rise when it announces an acquisition, more often than not, the acquirer's shares actually fall. The large jump in Valeant stock suggests that investors are very enthusiastic about the deal price and the potential synergies between the two companies. Valeant has now added 26% in 2012, and continues to be a very high performing pharmaceutical name.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&AIntraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!